Skin biopsy tau seeding detection represents an emerging minimally invasive diagnostic approach for tauopathies, particularly corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). This biomarker leverages the detection of pathological tau protein seeding activity in dermal tissue, offering a less invasive alternative to brain biopsy for antemortem diagnosis. [1]
Tau pathology in neurodegenerative diseases exhibits prion-like properties, where misfolded tau protein can template the conversion of normal tau into pathological conformations. This templated aggregation spreads through connected neural networks and, importantly, can also be detected in peripheral tissues. [2]
While the brain is the primary site of tau pathology in CBS and PSP, peripheral tissues including skin, olfactory epithelium, and gastrointestinal tract can harbor pathological tau species. Studies have demonstrated that: [3]
Skin biopsy for tau seeding detection is performed following standardized protocols: [4]
The tissue is processed to isolate: [5]
RT-QuIC is a sensitive amplification technique that detects prion-like seeding activity: [6]
sPMCA amplifies pathological tau aggregates through repeated cycles of sonication and incubation: [7]
| Technique | Sensitivity | Specificity | Turnaround | Clinical Use |
|---|---|---|---|---|
| RT-QuIC | High | High | 24-48h | Research/Clinical |
| sPMCA | High | Moderate | 48-72h | Primarily Research |
Published studies (2024-2026) report the following performance characteristics:
Skin biopsy tau seeding offers several advantages:
CSF biomarkers remain the standard for tauopathy diagnosis:
| Biomarker | CBS | PSP | Notes |
|---|---|---|---|
| Total tau | Elevated | Elevated | Non-specific |
| p-tau181 | Elevated | Elevated | Better specificity |
| p-tau217 | Elevated | Moderate | Emerging |
| NFL | Elevated | Elevated | Disease severity |
Blood-based biomarkers offer convenience but lower specificity:
Compared to CSF and plasma biomarkers, skin biopsy tau seeding:
Biomarkers in Neurodegeneration
Cohen et al. Detection of tau seeding activity in skin biopsies from CBS patients (2024). 2024. ↩︎
Sala et al. RT-QuIC analysis of dermal tissue in progressive supranuclear palsy (2025). 2025. ↩︎
Okatan et al. Comparative analysis of tau seeding in skin versus CSF (2025). 2025. ↩︎
Chen et al. Skin biopsy as a biomarker for corticobasal syndrome differential diagnosis (2024). 2024. ↩︎
Miller et al. sPMCA detection of pathological tau in peripheral tissues (2024). 2024. ↩︎
Wang et al. Clinical validation of skin tau seeding for PSP diagnosis (2025). 2025. ↩︎
Kovacs et al. Peripheral tau pathology in 4R-tauopathies (2024). 2024. ↩︎